Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Maintenance therapy (MT) with pemetrexed has been shown to improve overall and progression-free survival of patients with non-squamous non-small cell lung cancer (NSCLC), without impairing patients’ healthrelated quality of life (HRQOL) substantially. | Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer NSCLC Findings from a real-world setting